Esperion Therapeutics (ESPR) Finished Goods (2020)
Esperion Therapeutics (ESPR) posted Finished Goods of $418000.0 for Q2 2020, up 138.86% on a QoQ basis from $175000.0 in Q1 2020.
Esperion Therapeutics (ESPR) Finished Goods (2020) Analysis & Trends
Esperion Therapeutics' Finished Goods history runs 1 years deep, the most recent figure standing at $418000.0 for Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 418,000.00 |
| Mar 31, 2020 | 175,000.00 |